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Abstract
The objectives of the study were to investigate prevalence of cervical human papillomavirus
(HPV) genotypes to inform HPV vaccination strategy in South Africa and to study factors
associated with HPV prevalence. Sexually active, HIV-negative women, aged 16–22 years
recruited from Soweto (n = 143) and Cape Town (n = 148) were tested for cervical HPV and
other genital infections. Overall HPV prevalence was 66.7% (194/291) in young women.
Cape Town women were more likely to have multiple HPV infections than the Soweto
women (48.0%, 71/148 versus 35.0%, 50/143 respectively, p = 0.033) and probable HR-
HPV types (34.5%, 51/148 versus 21.7%, 31/143 respectively, p = 0.022). The most fre-
quently detected HPV types were HPV-16 (11.7%), HPV-58 (10.3%), HPV-51 (8.9%), HPV-
66 (8.6%), HPV-18 and HPV-81 (7.6% each). HPV types targeted by the bivalent HPV vac-
cine (HPV-16/18) were detected in 18.6% (54/291) of women, while those in the quadriva-
lent vaccine (HPV-6/11/16/18) were detected in 24.7% (72/291) of women; and those in the
nonavalent vaccine (HPV-6/11/16/18/31/33/45/52/58) were detected in 38.5% (112/291) of
women. In a multivariable analysis, bacterial vaginosis remained significantly associated
with HPV infection (OR: 4.0, 95% CI: 1.4–12.6). Women were more likely to be HPV positive
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if they had received treatment for STI during the past 6-months (OR: 3.4, 95% CI: 1.1–12.4)
or if they had ever been pregnant (OR: 2.3, 95% CI: 1.1–5.5). Compared to women who
reported only one sexual partner, those with increased number of lifetime sex partners were
more likely to have HPV (4–10 partners: OR: 2.9, 95% CI: 1.1–8.0). The high prevalence of
HPV types targeted by the nonavalent HPV vaccine encourages the introduction of this vac-
cine and catch-up HPV vaccination campaigns in South Africa. The high burden of BV and
concurrent STIs also highlights the need to improve the prevention and appropriate man-
agement of sexually-acquired and other genital tract infections in South African youth.
Introduction
Internationally, and in Africa, the majority of sexually transmitted infections (STIs) are in
young people [1, 2]. Human papillomavirus (HPV) is one of the most common STIs and in
women its prevalence peaks during adolescence, soon after sexual debut; and decreases with
increasing age [3]. Those women who sexually debuted at16 years are at higher risk for
being HPV infected [3]. The median age of first sexual debut in South African women ranges
from 16–18 years [4–6]. A high HPV prevalence in South African women <25 years of age has
been previously reported in Gauteng and KwaZulu Natal Provinces (85% and 76% respec-
tively) [7, 8]. In the Western Cape, estimates of HPV prevalence range from 44% to 71% [9–
11].
HPV natural history is influenced by several factors, such as infection with other STIs, early
sexual debut, increased number of lifetime sexual partners and increased numbers of current
sexual partners [12–14]. In women, STIs and bacterial vaginosis (BV) are very prevalent in
populations that are at high risk of human immunodeficiency virus (HIV) infection and
among women between the ages of 15–44 years [15, 16]. BV, a dysbiosis rather than an STI, is
thought to increase the risk of acquiring STIs [17].
There are currently three prophylactic HPV vaccines that are being rolled out internation-
ally: Cervarix, Gardasil and Gardasil-9. Cervarix protects against two high-risk HPV types,
HPV-16 and -18; Gardasil protects against two low-risk (LR) and two HR-HPV types, HPV-6,
-11, -16 and -18; while Gardasil-9 protects against five more types in addition to those targeted
by Gardasil, HPV-31, -33, -45, -52 and -58. Both Cervarix and Gardasil demonstrated cross
protective efficacy against phylogenetically related HPV-16 and -18 types, such as HPV-31,
-33, -45 and -51; however the duration of protection is not yet known. The efficacy, safety and
immunogenicity of these vaccines have been recognized in well followed cohorts [18–20].
South Africa introduced a school-based national HPV vaccination program in 2014; at
which time girls aged 9–10 years were vaccinated with Cervarix HPV vaccine and given in
two doses at least six-months apart (to fit into the academic calendar year). The data on HPV
genotype prevalence and distribution in unvaccinated populations is important to both inform
vaccination campaigns as well as to monitor the impact on circulating HPV types after vacci-
nation. As part of the HPV vaccination strategy in South Africa, it is important to have baseline
data in adolescents and young women to assess the impact of vaccination and improve HPV
vaccination strategies.
The primary objectives of this study were to investigate prevalence of cervical HPV infec-
tion in adolescent and young women, in particular the prevalence of HPV genotypes targeted
by current HPV vaccines, and the pattern of co-infection with sexually transmissible patho-
gens [HPV, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma
HPV in South African adolescents and young women
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genitalium, and herpes simplex virus-2 (HSV-2)]. The secondary objective was to study factors
associated with HPV prevalence in this population.
Materials and methods
Study population and specimen collection
Between November 2013 and December 2014, 298 sexually experienced HIV-negative black
women aged 16–22 years were recruited, all of whom were not vaccinated against HPV. Partic-
ipants were enrolled from two disadvantaged urban African communities in Cape Town
(South Peninsula) and Johannesburg (Soweto), South Africa, as part of the Women’s Initiative
in Sexual Health (WISH) study [21] through community outreach programs and adolescent
friendly sexual reproductive health services. The Human Research Ethics Committee of the
University of Cape Town (HREC reference 267/2013) and University of the Witwatersrand
(HREC reference M130745) approved the study. Written informed consent was obtained from
participants who were18 years while those who were 16–17 years old provided written
assent and consent was obtained from their parent or guardian.
A HIV rapid test (Alere Determine™ HIV-1/2 Ag/Ab Combo, Alere, Waltham, MA) was
performed. A lateral wall/posterior fornix swab was collected to determine vaginal pH and
presence of BV. Endocervical samples were collected from each woman under speculum
examination by clinicians using Digene cervical samplers (Digene Corporation Gaithersburg,
MD, USA) and stored in Digene transport medium at -80˚C until nucleic acid extraction.
Detection of STIs, BV and vaginal pH
Nucleic acid was extracted using MagNA Pure Compact Nucleic Acid Isolation Kit (Roche).
HPV genotyping was performed on extracted nucleic acid using the Roche Linear Array HPV
genotyping test (Roche Molecular Systems, Pleasanton, CA, USA) which identifies 37 different
HPV genotypes (HPV-6, -11, -16, -18, -26, -31, -33, -35, -39, -40, -42, -45, -51, -52, -53, -54,
-55, -56, -58, -59, -61, -62, -64, -66, -67, -68, -69, -70, -71, -72, -73, -81, -82, -83, -84, -89
(HPV-CP6108) and–IS39) [22].
Discharge-causing organisms C. trachomatis, N. gonorrhoeae, T. vaginalis, M. genitalium
and the ulcer-causing pathogens HSV and Treponema pallidum were diagnosed using two
real-time multiplex PCRs on vulvovaginal swabs [23]. HSV-positive DNA extracts were re-
tested and typed using a commercial HSV-1/HSV-2 PCR assay (Sacace Biotechnologies Srl,
Como, Italy). C. trachomatis serovars L1-L3 were detected using a simplex real-time PCR as
described by Morre´ et al. [24]. A lateral wall/posterior fornix swab was collected to determine
vaginal pH and presence of BV. Nugent criteria were used to assess BV [25]. Participants with
Nugent scores3 were considered BV negative, 4–6 to have intermediate vaginal flora, while
7–10 were considered to have BV. Vaginal pH was measured using colour-fixed indicator
strips (Macherey-Nagel, Du¨ren Germany). Participants with STI symptoms were treated
according to the syndromic management protocol. Those with STI positive laboratory results
were contacted to attend for treatment.
Statistical analyses
Data is first presented as combined for the two study sites, and further stratified by study sites
because the participants from Cape Town were found to have significantly higher risk behav-
iour than those in Soweto [21]. Multiple HPV infections were defined as detection of two or
more HPV types in the same sample. In cases where multiple infections were identified, indi-
viduals were counted as infected for the specific category if they have one or more infection in
HPV in South African adolescents and young women
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that category. However these women were counted more than once when determining the
prevalence of LR-HPV, HR-HPV and probable HR-HPV if they have types that belong to
more than one category.
“Logistic regression models assessed factors associated with baseline HPV prevalence. Mul-
tivariable models include factors that were simultaneously statistically significant at 5%, con-
sidering variables with p-value of less than 0.2 in the univariable analysis and manually
selecting the final model based on both the effect size and p-value. In the multivariable analysis
for HPV prevalence in both locations, the model was adjusted for location. Collinearity
between factors was investigated and not found. Statistical analyses were performed using
R”[26].
Results
HPV prevalence
HPV data were available for 291 of the 298 women recruited. The overall HPV prevalence in
these South African youth was 66.7% (194/291), being similarly prevalent in Cape Town and
Soweto (68.2%, 101/148 versus 65.0%, 93/143; p = 0.648). Cape Town women were, however,
more likely to have multiple HPV infections than the Soweto women (48.0%, 71/148 versus
35.0%, 50/143 respectively, p = 0.033) and probable HR-HPV types (34.5%, 51/148 versus
21.7%, 31/143 respectively, p = 0.022, Table 1). Overall, across the two sites, the most fre-
quently detected HPV types were HPV-16 (11.7%), HPV-58 (10.3%), HPV-51 (8.9%), HPV-66
(8.6%), HPV-18 and HPV-81 (7.6% each). In Cape Town participants, the most prevalent
HPV infections were HPV-58 (13.5%), HPV-16, HPV-51 and HPV-66 (10.8% each), HPV-53
(8.8%), HPV-68 and HPV-81 (8.1% each), HPV-61 and -83 (7.4% each). In the Soweto partici-
pants, HPV-16 (12.6%) was the most dominant type, followed by HPV-18 (8.4%), HPV-35
(7.7%), HPV-51, -58, -59 and 81 (7.0% each, Fig 1).
Prevalence of HPV types targeted by bivalent, quadrivalent and nonavalent
HPV vaccines
HPV types targeted by the bivalent HPV vaccine (HPV-16/18) were detected in 18.6% (54/
291) of women overall, while those found in the quadrivalent vaccine (HPV-6/11/16/18) were
detected in 24.7% (72/291) of women; and those in the nonavalent vaccine (HPV-6/11/16/18/
31/33/45/52/58) were detected in 38.5% (112/291) of women (Fig 2). Presently South Africa is
vaccinating with the Bivalent vaccine. HR-HPV types that are not targeted by bivalent,
Table 1. Prevalence of any human papillomavirus (HPV), multiple infections, single infection, HR-HPV, probable HR-HPV and LR-HPV.
OVERALL N = 291 CAPE TOWN, N = 148 SOWETO, N = 143 p-value
n, % (95% CI) n, % (95% CI) n, % (95% CI)
Any HPV 194, 66.7% (61.3–72.1%) 101, 68.2% (60.7–75.7%) 93, 65.0% (57.2–72.8%) 0.648
Multiple HPV infections 121, 41.6% (35.9–47.3%) 71, 48.0% (40.0–56.0%) 50, 35.0% (27.2–42.8%) 0.033
Single HPV infection 73, 25.1% (20.1–30.1%) 30, 20.3% (13.8–26.8%) 43, 30.1% (22.6–37.6%) 0.073
HR-HPV types 133, 45.7% (40.0–51.4%) 66, 44.6% (36.6–52.6%) 67, 46.9% (38.7–55.1%) 0.788
Probable HR-HPV types 82, 28.2% (23.0–33.4%) 51, 34.5% (26.8–42.2%) 31, 21.7% (14.9–28.5%) 0.022
LR-HPV types 112, 38.5% (32.9–44.1%) 64, 43.2% (35.2–51.2%) 48, 33.6% (25.9–41.3%) 0.115
 p-value of chi-square test to compare frequencies from Cape Town and Soweto sites.
HR-HPV: HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58 and -59. Probable HR-HPV: HPV-26, -53, -66, -67, -68, -70, -73 and -82. LR-HPV: HPV-6, -11, -40, 42,
-54, -55, -61, -62, -64, -69, -71, -72, -81, -83, -84, -89 (HPV-CP6108) and–IS39
https://doi.org/10.1371/journal.pone.0190166.t001
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quadrivalent or nonavalent HPV vaccines were observed in 21.0% (61/291 of the women
(HPV-35/39/56/59, Fig 2).
Fig 1. The prevalence of human papillomavirus genotypes according to study site in adolescents and young adults. HR-HPV types
included HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58 and -59; probably or possible HR-HPV types included HPV-26, -53, -66,
-67, -68, -70, -73 and -82; and low-risk (LR) HPV types HPV-6, -11, -40, 42, -54, -55, -61, -62, -64, -69, -71, -72, -81, -83, -84, -89
(HPV-CP6108) and–IS39 [22].
https://doi.org/10.1371/journal.pone.0190166.g001
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Prevalence and pattern of HPV co-infection with other STIs
HPV was the most prevalent STI detected (66.7% 194/291) in these adolescent and young
women. Co-infection with another STIs (including C. trachomatis, N. gonorrhoeae, T. vagina-
lis, M. genitalium or HSV-2) was observed in 44.0% (128/291) women while co-infection with
2 STIs was observed in 32.6% (95/291, Fig 3A). When investigating the pattern of infection
among women who presented with single STI infection, HPV was most prevalent (85.2%, 109/
128) followed by C. trachomatis (10.2%, 13/128, Fig 3B). Among 194 women that were HPV
positive, 56.2% (109/194) were infected with only HPV; 33.5% (65/194) were co-infected with
another STI (C. trachomatis, N. gonorrhoeae, T. vaginalis, M. genitalium or HSV-2) and 10.3%
(20/194) were infected with2 other STIs (Fig 3C). Among 97 women that were HPV nega-
tive, 70.1% (68/97) were not infected with any investigated STIs; 19.6% (19/97) were infected
with one STI (C. trachomatis, N. gonorrhoeae, T. vaginalis, M. genitalium or HSV-2) and 10.3%
(10/97) were infected with2 other STIs (Fig 3D). When further investigating women that
were infected with HPV and one other STI; HPV together with C. trachomatis was the most
common co-infection observed (70.8%, 46/65) followed by HPV/T. vaginalis co-infection
(12.3%, 8/65); HPV/N. gonorrhoeae co-infection (7.7%, 5/65); HPV/HSV-2 co-infection (4.6%,
3/65) and HPV/M. genitalium (4.6%, 3/65).
Factors associated with HPV prevalence in adolescents and young women
Overall, women with BV (Nugent score7) and those with intermediate vaginal flora (Nugent
4–6) were more likely to be HPV positive than women who were BV negative (Nugent3)
[odds ratio (OR): 2.8, 95% confidence interval (CI): 1.3–6.8; OR: 2.2, 95% CI: 1.3–3.7, respec-
tively]. Having a raised vaginal pH (>4.5) was not significantly associated with HPV infection
in women (OR: 1.7, 95% CI: 0.9–2.9). Women infected with any other STI were more likely to
have HPV infection than women with no STI (OR: 1.9, 95% CI: 1.2–3.3). Women who visited
Fig 2. Prevalence of human papillomavirus (HPV) types targeted by current vaccines and non-vaccine types.
Bivalent types: one or both HPV types targeted by the Cervarix HPV vaccine (HPV16/18); Quadrivalent types: one or
more HPV types targeted by the Gardasil HPV vaccine (HPV6/11/16/18); Nonavalent types: one or more HPV types
targeted by the Gardasil-9 HPV vaccine (HPV6/11/16/18/31/33/45/52/58); HR-HPV excluding vaccine & cross
protective types (HPV-35/39/56/59).
https://doi.org/10.1371/journal.pone.0190166.g002
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medical care facility to receive family planning (OR 1.8, 95% CI 1.0–3.4) or who had ever been
pregnant (OR 2.3, 95% CI 1.1–5.5) were more likely to be HPV positive than those who did
not (Table 2). Increased numbers of lifetime sexual partners was positively associated with
prevalent HPV (4–10 partners: OR 3.0, 95% CI 1.2–7.6); however, the age of sexual debut was
Fig 3. Pattern of sexual transmitted infection among South African adolescents and young women (A) Pattern of single infection (HPV or CT or NG or TV or MG
or HSV-2), co-infection with more than one of the six STIs; (B) Pattern of infection among women with one of the six investigated STIs; (C) Prevalence of co-
infectionsa among South African adolescents and young women with one or more sexual transmitted infections. a among 194 women that were HPV positive, 56%
were positive for HPV only (Solo infection); 34% were co- infected with CT or NG or TV or MG or HSV-2 and 10% were infected with2 other STI; (D) Prevalence
of co-infectionsb among South African adolescents and young women with one or more sexual transmitted infections. b among 97 women that were HPV negative,
70% were negative for all tested STIs, 20% were infected with CT or NG or TV or MG or HSV-2 and 10% were infected with2 other STI. HPV: Human
papillomavirus. CT: Chamydia trachomatis. NG: Neisseria gonorrhoeae. TV: Trichomanas vaginalis. MG: Mycoplasma genitalium. HSV-2: Herpes simplex virus-2.
https://doi.org/10.1371/journal.pone.0190166.g003
HPV in South African adolescents and young women
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Table 2. Human papillomavirus prevalence and factors associated with human papillomavirus in adolescents and young women (univariate analysis).
OVERALL CAPE TOWN SOWETO
Variable HPV
prevalence
OR (95%
CI)
p-value HPV
prevalence
OR (95%
CI)
p-value HPV
prevalence
OR (95%
CI)
p-value
Age 1.0 (0.9–1.2) 0.897 0.8 (0.7–1.0) 0.110 1.2 (1.0–1.5) 0.117
Bacterial Vaginosis
negative 62/113 (55%) ref 37/61 (61%) ref 25/52 (48%) ref
intermediate 95/131 (73%) 2.2 (1.3–3.7) 0.004 51/70 (73%) 1.7 (0.8–3.7) 0.140 44/61 (72%) 2.8 (1.3–6.2) 0.010
positive 31/40 (78%) 2.8 (1.3–6.8) 0.014 13/17 (77%) 2.1 (0.7–8.2) 0.236 18/23 (78%) 3.9 (1.3–
13.2)
0.019
Chlamydia trachomatis
negative 128/201
(63.7%)
ref 57/86 (66%) ref 71/115 (62%) ref
positive 64/87 (73.6%) 1.6 (0.9–2.8) 0.104 44/62 (71%) 1.2 (0.6–2.6) 0.546 20/25 (80%) 2.5 (0.9–7.9) 0.090
Neisseria gonorrhoeae
negative 175/264 (66%) Ref 90/131 (69%) ref 85/133 (64%) ref
positive 17/24 (70.8%) 1.2 (0.5–3.3) 0.652 11/17 (65%) 0.8 (0.3–2.6) 0.739 6/7 (86%) 3.4 (0.6–65) 0.265
Trichomonas vaginalis
negative 181/272 (67%) ref 93/137 (68%) ref 88/135 (65%) ref
positive 11/16 (69%) 1.1 (0.4–3.6) 0.856 8/11 (73%) 1.3 (0.4–6.0) 0.740 3/5 (60%) 0.8 (0.1–6.2) 0.812
Mycoplasma genitalium
negative 185/278 (67%) ref 97/142 (68%) ref 88/136 (65%) ref
positive 7/10 (70%) 1.2 (0.3–5.5) 0.820 4/6 (67%) 0.9 (0.2–6.9) 0.933 3/4 (75%) 1.6 (0.2–
33.6)
0.673
Herpes simplex virus-2
negative 185/280 (66%) ref 95/141 (67%) ref 90/139 (65%) . . .
positive 7/8 (88%) 3.6 (0.6–
67.7)
0.235 6/7 (86%) 2.9 (0.5–
55.7)
0.330 1/1 (100%) . . . 0.987
Any STI
negative 107/175 (61%) ref 44/71 (62%) ref 63/104 (61%) ref
positive 85/113 (75%) 1.9 (1.2–3.3) 0.014 57/77 (74%) 1.8 (0.9–3.6) 0.117 28/36 (78%) 2.3 (1.0–5.8) 0.066
Vaginal pH
4.5 43/74 (58%) ref 26/44 (59%) ref 17/30 (57%) ref
>4.5 137/197 (70%) 1.7 (0.9–2.9) 0.077 68/95 (72%) 1.7 (0.8–3.7) 0.145 69/102 (68%) 1.6 (0.7–3.7) 0.269
Received treatment of STIs in past 6
months
No 119/181 (66%) ref 69/102 (68%) ref 50/79 (63%) ref
Yes 22/26 (85%) 2.9 (1.0–
10.1)
0.063 12/14 (86%) 2.9 (0.7–
19.1)
0.183 10/12 (83%) 2.9 (0.7–
19.7)
0.188
Family planning received past 6
months
No 44/74 (60%) ref 13/21 (62%) ref 31/53 (59%) ref
Yes 97/133 (73%) 1.8 (1.0–3.4) 0.047 68/95 (72%) 1.6 (0.6–4.1) 0.384 29/38 (76%) 2.3 (0.9–6.0) 0.080
HIV testing received past 6 months
No 50/81 (62%) ref 18/25 (72%) ref 32/56 (57%) ref
Yes 91/126 (72%) 1.6 (0.9–2.9) 0.115 63/91 (69%) 0.9 (0.3–2.3) 0.789 28/35 (80%) 3.0 (1.2–8.5) 0.028
Ever pregnant
No 95/150 (63%) ref 58/86 (67%) ref 37/64 (58%) ref
Yes 46/57 (81%) 2.4 (1.2–5.3) 0.019 23/30 (77%) 1.6 (0.6–4.4) 0.346 23/27 (85%) 4.2 (1.4–
15.6)
0.016
Prefer male condom for contraception
(Continued)
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not associated with HPV. Women who reported a preference for male condom as their pri-
mary form of contraception were less likely to have HPV infection than those who preferred
other methods (OR 0.5, 95% CI 0.3–1.0), although the frequency of reported male condom use
was not associated with prevalent HPV (Table 2).
In a multivariable analysis, BV remained significantly associated with HPV infection (OR:
4.0, 95% CI: 1.4–12.6). Women were more likely to be HPV positive if they had received treat-
ment for STI during the past 6-months (OR: 3.4, 95% CI: 1.1–12.4) or if they had ever been
pregnant (OR: 2.3, 95% CI: 1.1–5.5). Compared to women who reported only one sexual part-
ner, those with increased number of lifetime sex partners were more likely to have HPV (4–10
partners: OR: 2.9, 95% CI: 1.1–8.0; Table 3).
When young women were grouped according to study site, those from Soweto with BV
(Nugent score7) and those with intermediate BV (Nugent 4–6) were more likely to be HPV
positive than women who were BV negative (Nugent3, OR: 3.9, 95% CI: 1.3–13.2; OR: 2.8,
95% CI: 1.3–6.2, respectively). Soweto women who visited a medical care facility to receive an
HIV test during the past 6-months (OR 3.0, 95% CI 1.2–8.5) or those who had ever been preg-
nant (OR 4.2, 95% CI 1.4–15.6) were more likely to be HPV positive. Reported increased num-
bers of lifetime sex partners in Soweto was positively associated with HPV prevalence (2–3
partners: OR 3.4, 95% CI 1.3–9.4 and 4–10 partners: OR 5.6, 95% CI 1.5–27.2). In addition,
Sowetan women who reported HIV-positive sexual partners were less likely to have HPV
infection than those who reported only HIV-negative partners or partners of unknown HIV
status (OR 0.3, 95% CI 0.1–0.8, Table 2).
In a multivariable analysis including only Sowetan participants, BV remained significantly
associated with HPV infection (OR 7.2, 95% CI 1.5–45.2). Sowetan women who reported only
one sexual partner, women with an increased numbers of lifetime sex partners were more
likely to have HPV (2–3 partners: OR 5.9, 95% CI 1.8–22.0; 4–10 partners: OR 9.3, 95% CI
2.0–57.7). Sowetan women who reported sex with HIV-positive partners were less likely to
have HPV infections than those reporting HIV negative partners or partners of unknown HIV
Table 2. (Continued)
OVERALL CAPE TOWN SOWETO
Variable HPV
prevalence
OR (95%
CI)
p-value HPV
prevalence
OR (95%
CI)
p-value HPV
prevalence
OR (95%
CI)
p-value
No 113/157 (72%) ref 73/103 (71%) ref 40/54 (74%) ref
Yes 28/50 (56%) 0.5 (0.3–1.0) 0.037 8/13 (62%) 0.7 (0.2–2.3) 0.492 20/37 (54%) 0.4 (0.2–1.0) 0.050
Sexual partner/s HIV positive
(Discordancy)
No 117/164 (71%) ref 73/105 (70%) ref 44/59 (75%) ref
Yes 24/43 (56%) 0.5 (0.3–1.0) 0.054 8/11 (73%) 1.2 (0.3–5.6) 0.826 16/32 (50%) 0.3 (0.1–0.8) 0.020
Age at first sex
12–15 years 48/64 (75%) ref 31/38 (82%) ref 17/26 (65%) ref
16–17 years 72/114 (63%) 0.6 (0.3–1.1) 0.108 40/64 (63%) 0.4 (0.1–1.0) 0.047 32/50 (64%) 0.9 (0.3–2.5) 0.905
18–20 years 13/18 (72%) 0.9 (0.3–3.0) 0.812 4/6 (67%) 0.5 (0.1–3.7) 0.409 9/12 (75%) 1.6 (0.4–8.5) 0.555
Number of lifetime sexual partners
1 32/58 (55%) ref 15/22 (68%) ref 17/36 (47%) ref
2–3 71/101 (70%) 1.9 (1.0–3.8) 0.056 44/65 (68%) 1.0 (0.3–2.7) 0.966 27/36 (75%) 3.4 (1.3–9.4) 0.018
4–10 33/42 (79%) 3.0 (1.2–7.6) 0.018 18/24 (75%) 1.4 (0.4–5.2) 0.609 15/18 (83%) 5.6 (1.5–
27.2)
0.016
BV: bacterial vaginosis. BV Negative: nugent score <4. BV inter: nugent score 4–6. BV Positives: nugent score7. OR: odds ratio. CI: confidence interval.
https://doi.org/10.1371/journal.pone.0190166.t002
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status (OR 0.2, 95% CI 0.0–0.5; Table 3). Among Cape Town girls, only age at first sex was
related to HPV positivity. In contrast to women from Soweto, there was no significant associa-
tion between HPV prevalence and other factors for participants from Cape Town.
Discussion
We have described HPV prevalence among adolescents and young women from two Provinces
of South Africa. Among these HIV-negative young women, the high overall HPV prevalence
(66.7%) and high HPV-16 prevalence (11.7%) is of substantial public health concern. HPV-16
is the dominant HPV type in cervical cancer cases occurring in more than 50% of cervical can-
cers [12]. Furthermore, HPV-16 is also the most carcinogenic HPV and more likely to persist
than other HPV types. After 3–5 years of persistent infection, HPV-16 is reported to have a
risk of a pre-cancer diagnosis of nearly 40% [27].
A high HPV prevalence among adolescents and young women has previously been
reported in Gauteng, KwaZulu Natal and Western Cape Provinces of South Africa [8–11].
There was no difference in the prevalence of HPV infection between Cape Town (Western
Cape) and Soweto (Gauteng) in this study. The high HPV prevalence seen in this population
Table 3. Human papillomavirus prevalence and factors associated with human papillomavirus in adolescents and
young women (multivariable analysis).
Variable aOR (95% CI) p-value
OVERALL PARTICIPANTS
Bacterial Vaginosis
negative ref
intermediate 2.6 (1.3–5.2) 0.007
positive 4.0 (1.4–12.6) 0.012
Received treatment of STIs in past 6 months
No ref
Yes 3.4 (1.1–12.4) 0.042
Ever pregnant
No ref
Yes 2.3 (1.1–5.5) 0.040
Number of lifetime sexual partners
1 ref
2–3 1.9 (0.9–4.0) 0.110
4–10 2.9 (1.1–8.0) 0.036
SOWETO PARTICIPANTS
Bacterial Vaginosis
negative ref
intermediate 4.7 (1.5–16.6) 0.011
positive 7.2 (1.4–45.2) 0.020
Sexual partner/s HIV positive (Discordancy)
No ref
Yes 0.2 (0.04–0.5) 0.003
Number of lifetime sexual partners
1 ref
2–3 5.9 (1.8–22.0) 0.005
4–10 9.3 (2.0–57.7) 0.008
https://doi.org/10.1371/journal.pone.0190166.t003
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of HIV-negative adolescents and young women puts them at increased risk of HIV acquisition
[9, 28]. The association between HIV and HPV is well documented, with HPV increasing the
risk of HIV acquisition and in turn HIV increasing the risk of HPV acquisition and persistence
[29, 30]. Even though adolescents are at low risk of cervical cancer, HIV-positive adolescents
are at high risk for abnormal cervical cytology and are more likely to have persistent HPV
infections [11, 31].
We acknowledge that HPV types targeted by vaccines should be studied in cervical cancer
studies and that the HPV prevalence in a young population with no cervical cancer does not
reflect the proportion of types found in cancers. However, the high prevalence (38.5%) of HPV
types targeted by the Gardasil-9 HPV vaccine in this population encourages the introduction
of Gardasil-9. This vaccine targets seven HPV types that cause cancer, and two HPV types that
cause genital warts. In South Africa, coverage of more than 90% was achieved in 2014 when a
national school based HPV vaccination programme was introduced in public schools for girls
of 9–10 years of age [32]. Our results illustrate the high prevalence of HPV in young women
and support the continuation of large scale roll-out of HPV vaccination to South African girls
and the establishment of catch-up campaigns for young adolescents.
The current HPV vaccines are prophylactic and are not effective in women who are already
infected with HPV; therefore continuation of cervical cancer screening programs is essential
in order to reduce cervical cancer through early detection of cervical precancerous lesions and
treatment among women who are already HPV infected, unvaccinated or partially vaccinated
women, and those infected with HPV types not targeted by current HPV vaccines. The high
prevalence of HR-HPV types that are not targeted by current vaccines (23.4%), specifically
HPV-51 and HPV-35, also raises concern in this population. HPV 51 and 35 have been
reported in 2.1% and 9.7% of African cervical cancers respectively [33].
A high burden of concurrent STIs was observed in this study, similar to a recently reported
study among Western Cape young women [34]. In addition to HPV, other STIs increase the
risk of HIV acquisition and transmission [35]. Here, we also found an association between BV
and HPV. BV has been previously associated with prevalent or new HPV infections and low
grade squamous intraepithelial lesions [36, 37]. However, women with high vaginal pH were
not more likely to be HPV infected than women with low vaginal pH; implying the mecha-
nisms of BV-induced barrier disruption may be independent of pH. Instead, inflammation
induced by specific vaginal microbiota may compromise barrier integrity [38]. It has been also
shown that specific bacteria associated with BV such as Gardnerella vaginalis are associated
with host-epithelium disruption and that soluble products from these bacteria inhibited
wound healing. It is therefore feasible that the same proposed mechanism that increased the
risk of HIV infection could also result in increased HPV infection in women with BV [39].
Women that do not have BV but have a vaginal microbiota dominated by Lactobacillus crispa-
tus have lower prevalent HPV implying that L. crispatus may provide protection from HPV
infection whereas greater microbiota diversity is associated with cervical intraepithelial neopla-
sia disease progression [40, 41]. Among Soweto participants there was an association between
BV with HPV but not among Cape Town participants. This could be due to the high preva-
lence of HPV (61%) in BV negative Cape Town participants compared to Sowetan where 48%
of the BV negative women were HPV positive.
As expected, sexual behaviour had an impact on HPV prevalence. Increased number of life-
time sexual partners, pregnancy, infection with other STIs and prior treatment for STIs were
associated with HPV prevalence in multivariable analysis. Increased number of pregnancies
and early maternal age at first birth were associated with increased risk of cervical cancer [42].
HPV infection was less likely among women who reported having an HIV-positive sexual
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partner than those with HIV-negative or unknown partner’s HIV status. These findings could
reflect increased frequency of condom usage among this group [43].
It is important to note that current study participants we recruited from sexual reproductive
health services and community outreach programs. According to second South African
National Youth Risk Behaviour Survey conducted in nine Provinces of South Africa; 41% of
sexual active participants reported to have had more than 2 sexual partners in lifetime; 4.4%
reported ever having had STI and 19.2% had been pregnant. In contrast, 71.1% (57/207) of
current study participants reported to have had more than 2 lifetime sexual partners; 15.0%
(36/207) reported ever having STI and 27.5% to have been pregnant. Therefore; current study
participants have high risk sexual behaviour compared to general population.
Conclusion
This study observed high HPV prevalence in adolescents and young HIV-negative women.
The high prevalence of HPV types targeted by current HPV vaccines especially HPV-16, sug-
gests that young South African women would greatly benefit from HPV vaccination. The high
prevalence of HPV types targeted by Gardasil-9 HPV vaccine supports the introduction of
Gardasil-9 HPV vaccine as this vaccine targets larger number of HR-HPV types that cause can-
cer. These findings also encourage the continuation of large scale roll-out of HPV vaccination
and catch-up programs in South Africa. The findings of this study could help inform health
policy makers by providing useful HPV baseline data for assessing the impact of HPV vaccina-
tion in these communities, and possibly assist in development of policy to improve HPV vacci-
nation strategies. The high burden of BV and concurrent STIs also highlights the urgent need
to improve the prevention, detection and appropriate management of sexually-acquired and
other genital tract infections in adolescents and young women in South Africa.
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